IMMUNITYBIO, INC. Repayments of Long-term Capital Lease Obligations
IMMUNITYBIO, INC. (IBRX) reported Repayments of Long-term Capital Lease Obligations of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermCapitalLeaseObligations · last filed 2021-03-04
- IMMUNITYBIO, INC. repayments of long-term capital lease obligations for the quarter ending 2018-12-31 was $142.00K, a 121.88% increase year-over-year.
- IMMUNITYBIO, INC. repayments of long-term capital lease obligations for the quarter ending 2018-09-30 was $137.00K, a 99.08% decline year-over-year.
- IMMUNITYBIO, INC. repayments of long-term capital lease obligations for the quarter ending 2018-06-30 was $133.00K, a 97.28% decline year-over-year.
- IMMUNITYBIO, INC. repayments of long-term capital lease obligations for the quarter ending 2018-03-31 was $65.00K, a 195.45% increase year-over-year.
- IMMUNITYBIO, INC. repayments of long-term capital lease obligations for fiscal 2020 was $0.00.
- IMMUNITYBIO, INC. repayments of long-term capital lease obligations for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- IMMUNITYBIO, INC. repayments of long-term capital lease obligations for fiscal 2018 was $477.00K, a 97.61% decline from fiscal 2017.
- IMMUNITYBIO, INC. repayments of long-term capital lease obligations for fiscal 2017 was $19.93M, a 62187.50% increase from fiscal 2016.
| Period end | Repayments of Long-term Capital Lease Obligations 3 month | Repayments of Long-term Capital Lease Obligations 6 month | Repayments of Long-term Capital Lease Obligations 9 month | Repayments of Long-term Capital Lease Obligations 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-04 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-04 | |||
| 2018-12-31 | $142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $279.00K derived: sum of 2 quarters · filed 2021-03-04 | $412.00K derived: sum of 3 quarters · filed 2021-03-04 | $477.00K 10-K · filed 2021-03-04 |
| 2018-09-30 | $137.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $270.00K derived: sum of 2 quarters · filed 2018-11-07 | $335.00K 10-Q · filed 2018-11-07 | $399.00K derived: sum of 4 quarters · filed 2020-03-25 |
| 2018-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $198.00K 10-Q · filed 2018-08-06 | $262.00K derived: sum of 3 quarters · filed 2020-03-25 | $15.21M derived: sum of 4 quarters · filed 2020-03-25 |
| 2018-03-31 | $65.00K 10-Q · filed 2018-05-07 | $129.00K derived: sum of 2 quarters · filed 2020-03-25 | $15.08M derived: sum of 3 quarters · filed 2020-03-25 | $19.98M derived: sum of 4 quarters · filed 2020-03-25 |
| 2017-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $15.01M derived: sum of 2 quarters · filed 2020-03-25 | $19.91M derived: sum of 3 quarters · filed 2020-03-25 | $19.93M 10-K · filed 2020-03-25 |
| 2017-09-30 | $14.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $19.85M derived: sum of 2 quarters · filed 2018-11-07 | $19.87M 10-Q · filed 2018-11-07 | $19.89M derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-06-30 | $4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $4.92M 10-Q · filed 2018-08-06 | $4.94M derived: sum of 3 quarters · filed 2019-03-13 | $4.95M derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-03-31 | $22.00K 10-Q · filed 2018-05-07 | $44.00K derived: sum of 2 quarters · filed 2019-03-13 | $54.00K derived: sum of 3 quarters · filed 2019-03-13 | $54.00K derived: sum of 4 quarters · filed 2019-03-13 |
| 2016-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $32.00K derived: sum of 2 quarters · filed 2019-03-13 | $32.00K derived: sum of 3 quarters · filed 2019-03-13 | $32.00K 10-K · filed 2019-03-13 |
| 2016-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $10.00K derived: sum of 2 quarters · filed 2017-11-07 | $10.00K 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $0.00 10-Q · filed 2017-08-07 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-08 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |